New Zealand Approves MDMA for PTSD Treatment
Translated from Danish and summarized by DistantNews. Read the original for the full story.
At a glance
- New Zealand regulator Medsafe approved two psychiatrists to prescribe pharmaceutical-grade MDMA for people with severe PTSD.
- New Zealand became the second country to approve MDMA for PTSD treatment, after Australia authorized the use in 2023.
- Deputy Prime Minister David Seymour said PTSD destroys lives and that MDMA could be effective when used in psychedelic-assisted therapy.
New Zealand has become the second country in the world to approve pharmaceutical-grade MDMA for treating severe post-traumatic stress disorder.
The regulator Medsafe authorized two psychiatrists to prescribe the drug to people with serious PTSD. Australia became the first country to approve the specific use in 2023.
PTSD can develop after severe psychological trauma, including accidents, war, disasters and abuse. The condition can last for a relatively long time and can sometimes become persistent.
PTSD destroys lives and is difficult to treat.
โPTSD destroys lives and is difficult to treat,โ Deputy Prime Minister David Seymour said. He also supported New Zealandโs approval last year of psychedelic mushrooms for people with severe depression.
โMDMA can be very effective in treatment through psychedelic-assisted therapy,โ Seymour said.
MDMA can be very effective in treatment through psychedelic-assisted therapy.
Originally published by Berlingske in Danish. Translated, summarized, and contextualized automatically by DistantNews, with a note on how the source frames the story. Not individually reviewed before publishing. How this works.